Hannah Mamuszka is Founder and Chief Executive Officer at Alva10, a strategy and investment firm which she founded in 2015 to address the ‘vicious cycle’ of diagnostics- inadequate reimbursement leading to inadequate investment preventing promising diagnostic technology from impacting patient care. Alva10 partners with payers, employers, and diagnostic developers to develop diagnostic tools to address major areas of healthcare need, inefficient spending and poor patient outcomes. Prior to Alva10, Hannah was VP of Exosome Diagnostics (acquired by BioTechne), where she led some of the earliest deals in the liquid biopsy diagnostic space.
Earlier in her career, she was Global Director of Pharmaceuticals Services for Oncotech, and then by acquisition, Exiqon (acquired by QIAGEN). Prior to her time in diagnostics, she worked in drug development on VelcadeTM at Millennium Pharmaceuticals (acquired by Takeda). She started her laboratory career at the National Institutes of Health, holding laboratory positions in both the National Cancer Institute (NCI) and the National Institute of Allergy and Infectious Disease (NIAID).
She earned a BS from the University of Maryland, College Park in Neurobiology and Physiology, and an MS in Biological Sciences from Harvard University. Hannah is a frequent speaker and writer on Precision Medicine, the impact of healthcare technology, and health economics and writes a regular column for the Journal of Precision Medicine on the challenges of implementing change in healthcare. Hannah serves on the Board of Directors for Bionano Genomics (BNGO) and Circle Cardiovascular, as well as on the Advisory Board for the Carolina Health Informatics Program (CHIP), a graduate program in health informatics at the University of Carolina at Chapel Hill.